Financial reports
10-K
2023 FY
Annual report
11 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
8-K
Olema Oncology JP Morgan Conference January 2024
8 Jan 24
8-K
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
8 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5 Dec 23
8-K
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
23 Oct 23
8-K/A
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
18 Oct 23
8-K
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
17 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
11 Mar 24
424B3
Prospectus supplement
12 Feb 24
S-3
Shelf registration
31 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
D
$130.00 mm in equity, sold $130.00 mm, 12 investors
14 Sep 23
424B5
Prospectus supplement for primary offering
9 Mar 23
S-8
Registration of securities for employees
9 Mar 23
S-3
Shelf registration
28 Feb 22
S-8
Registration of securities for employees
28 Feb 22
S-8
Registration of securities for employees
17 Mar 21
Other
EFFECT
Notice of effectiveness
12 Feb 24
UPLOAD
Letter from SEC
7 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
EFFECT
Notice of effectiveness
3 May 22
CORRESP
Correspondence with SEC
28 Apr 22
UPLOAD
Letter from SEC
4 Mar 22
EFFECT
Notice of effectiveness
19 Nov 20
CERT
Certification of approval for exchange listing
18 Nov 20
SEC STAFF
SEC staff action: Order
17 Nov 20
CORRESP
Correspondence with SEC
16 Nov 20
Ownership
4
Cyrus Harmon
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
4
Naseem Zojwalla
20 Mar 24
4
ANDREW RAPPAPORT
6 Mar 24
4
Cyrus Harmon
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
Kynam Capital Management, LP
14 Feb 24